TILT Biotherapeutics Ltd is the leading company globally working in the area of enabling tumor.
TILT Biotherapeutics is the leading company globally working in the area of enabling tumor T-cell therapy with oncolytic viruses. TILT is a preclinical stage company working in the field of cancer immunotherapy and will soon translate its unique approach into clinical trials. The company’s patented technology involves utilization of oncolytic viruses for enhancement of tumor T-cell therapy. Initial embodiments of the technology will be used to enhance tumor infiltrating lymphocyte (TIL), chimeric antigen receptor (CAR-T) and checkpoint inhibiting antibody therapy. The TILT approach has the potential to achieve similar results in CAR-T therapy of solid tumors as currently achieved for CD19+ hematological tumors.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Feb 7, 2023 | Series Unknown | €9.90M | 2 | European Innovation Council | — | Detail |
Feb 7, 2023 | Grant | €2.10M | 1 | European Innovation Council | — | Detail |
Dec 14, 2016 | Seed | €10M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
European Innovation Council | Yes | Series Unknown |
ACME Investments | — | Series Unknown |
Keksintösäätiö | — | Seed |